

Q2 Half-yearly report

January–June 2025



DETECTION TECHNOLOGY PLC HALF-YEARLY REPORT JANUARY-JUNE 2025

Detection Technology Q2 2025: Sales declined, yet the company's market position remained solid**April-June 2025 highlights**

- Net sales decreased by -6.6% to EUR 24.4 million (26.1)
- Net sales of Americas decreased by -5.2% to EUR 1.5 million (1.6)
- Net sales of APAC (Asia-Pacific) increased by 8.6% to EUR 18.2 million (16.7)
- Net sales of EMEIA (Europe, Middle East, India and Africa) decreased by -39.6% to EUR 4.7 million (7.8)
- Net sales of industrial applications increased by 4.2% to EUR 5.6 million (5.3)
- Net sales of medical applications increased by 13.9% to EUR 10.6 million (9.3)
- Net sales of security applications decreased by -28.2% to EUR 8.2 million (11.5)
- Operating profit (EBITA) was EUR 1.7 million (3.3)
- Operating margin (EBITA-%) was 7.0% of net sales (12.7%)
- Return on investment (ROI, 12-month rolling) was 14.7% (13.9%)

January-June 2025 highlights

- Net sales decreased by -4.5% to EUR 46.6 million (48.8)
- Net sales of Americas decreased by -4.8% to EUR 2.4 million (2.5)
- Net sales of APAC increased by 5.5% to EUR 34.2 million (32.4)
- Net sales of EMEIA decreased by -27.5% to EUR 10.1 million (13.9)
- Net sales of industrial applications increased by 4.2% to EUR 9.3 million (8.9)
- Net sales of medical applications increased by 13.8% to EUR 21.4 million (18.8)
- Net sales of security applications decreased by -24.4% to EUR 15.9 million (21.1)
- Operating profit (EBITA) was EUR 3.1 million (5.6)
- Operating margin (EBITA-%) was 6.7% of net sales (11.4%)

(Figures in parentheses refer to the corresponding period of the previous year.)

Business outlook

Detection Technology expects a single digit year-on-year net sales decline in Q3 and H2 of 2025.

The geopolitical situation, new U.S. import tariffs, U.S. relations with other countries, China's healthcare reform, and price competition especially in China create uncertainty.

Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.

President and CEO, Hannu Martola:

"Our Q2 total net sales were a disappointment. Security CT system installations nearly halted in Europe, and EMEIA sales declined sharply. Over half of the sales decline was due to currency fluctuations. However, our position in key markets remained stable. We also maintained strong momentum in flat panel detector sales and strategic execution.

Demand for medical CT applications strengthened, particularly in China, where the backlog from healthcare reforms continued to clear. Sales of our flat panel detector portfolio for industrial applications also developed strongly, growing approximately 40% year-on-year in H1.

In contrast, the dip in demand for security applications was deeper than expected, leading to a sharp decline in EMEIA sales. The halt in security CT system installations in aviation in Europe—partly due to the so-called 100 ml liquid rule—weighed on performance. The strong comparison period also added pressure to the topline. Despite softer-than-expected sales, our market position in security CT remained intact.

Lower-than-expected quarterly sales and a less favorable sales mix eroded our profitability. Our profitability development has been unsatisfactory. To that end, appropriate cost measures are now being taken.

In Q2, we rolled out several notable products. Sales of the X-Panel 43108 flat panel detector, launched for single-scan imaging of large components in the automotive, aerospace, and defense industries, have started off successfully. We also introduced the X-Cargo for high-speed, high-energy cargo and industrial imaging. Supporting scanning speeds up to 70 km/h, the solution is already selling well for border security applications.

The expansion of our operations in India is progressing. The production facility has been completed, and the first products have been tested. We also invested in new technology to support long-term innovations and growth.

We are renewing our strategy for the next five-year period. We will deliver smart X-ray detector solutions that drive customer success through exceptional usability to outgrow the market. We continue to work on the strategy details and execution planning.

Looking ahead, we expect demand in both medical and security CT applications to start normalizing. In China, the recovery in medical demand continues following anti-corruption measures, but the new block purchasing model is intensifying competition. The regulatory bottleneck in European aviation will move away, as testing specifications for CT systems have been approved, and the equipment from a certain OEM has been recertified. We expect the security CT sales to be back on track by the end of the year. Industrial demand, particularly in defense, is increasing. However, visibility remains limited due to the impact of new tariffs, ongoing macroeconomic uncertainty, and constrained availability of certain electronic components.

In Q3, the APAC region indicates strengthening medical demand, but our sales are constrained mainly by component availability and therefore will remain stable. Demand for security applications is picking up slowly, leading to flat sales in EMEIA, while sales in the Americas are expected to decline by double digits. Following an estimated 5% currency impact, we expect year-on-year total net sales to decline by a single digit in Q3 and H2 of 2025."

Key figures

(EUR 1,000)	4-6/2025	4-6/2024	1-6/2025	1-6/2024	1-12/2024
Net sales	24,372	26,093	46,621	48,799	107,514
Change in net sales, %	-6.6%	3.5%	-4.5%	1.7%	3.6%
EBITA	1,702	3,306	3,101	5,570	14,892
EBITA, %	7.0%	12.7%	6.7%	11.4%	13.9%
R&D costs	3,146	3,049	5,781	5,560	11,379
R&D costs, % of net sales	12.9%	11.7%	12.4%	11.4%	10.6%
Cash flow from operating activities	458	3,911	1,897	6,827	20,133
Net interest-bearing debt at end of period	-19,794	-14,744	-19,794	-14,744	-27,767
Investments	1,144	352	1,548	1,485	2,218
Return on investment (ROI), %	14.7%	13.9%	14.7%	13.9%	17.4%
Gearing, %	-27.2%	-19.9%	-27.2%	-19.9%	-33.6%
Earnings per share, EUR	0.07	0.15	0.11	0.26	0.76
Earnings per share (diluted), EUR	0.07	0.15	0.11	0.26	0.76
Number of shares at the end of the period	14,655,630	14,655,930	14,655,630	14,655,930	14,655,930
Weighted average number of shares outstanding	14,655,630	14,655,930	14,655,730	14,655,930	14,655,930
Weighted average number of shares outstanding, diluted	14,655,630	14,661,754	14,657,943	14,658,842	14,660,744

Net sales

In Q2 2025, Detection Technology's total net sales decreased by -6.6% (3.5%) and amounted to EUR 24.4 (26.1) million. The decline in sales was primarily due to prolonged softness in the security segment and unfavorable currency effects.

Demand for medical CT applications strengthened, particularly in China, where backlogs related to anticorruption campaign targeting healthcare providers continued to clear. In contrast, the security application segment experienced a longer-than-anticipated dip in demand, leading to a sharp decline in EMEA sales. This was due to delays in aviation security CT system installations—partly due to the postponed implementation of the 100 ml liquid rule—and a strong comparison period. Exchange rate fluctuations added additional pressure on the topline, with the decline in net sales being less severe when adjusted for currency effects.

In Q2, the APAC business unit's net sales increased by 8.6% (2.0%) and were EUR 18.2 (16.7) million. The EMEA business unit's net sales declined by -39.6% (49.1%) and were EUR 4.7 (7.8) million. The Americas business unit's net sales declined by -5.2% (-56.3%) and were EUR 1.5 (1.6) million. APAC accounted for 74.6% (64.2%) of the company's total net sales, EMEA for 19.3% (29.8%), and the Americas for 6.1% (6.0%).

Net sales from medical applications increased by 13.9% (-25.3%) and were EUR 10.6 (9.3) million. Net sales from security applications decreased by -28.2% (26.7%) and were EUR 8.2 (11.5) million. Net sales from industrial applications increased by 4.2% (42.6%) and were EUR 5.6 (5.3) million. Medical applications accounted for 43.3% (35.5%) of total net sales, security applications 33.8% (44.0%), and industrial applications 22.8% (20.5%).

The share of the five largest customers in Detection Technology's total net sales was 51.8% (51.3%).

In H1 2025, the company's total net sales decreased by -4.5% (1.7%) and were EUR 46.6 million (48.8). Net sales of APAC increased by 5.5% (2.2%) and were EUR 34.2 million (32.4). Net sales of EMEA decreased by -27.5%

(36.6%) and were EUR 10.1 million (13.9). Net sales of Americas decreased by -4.8% (-59.4%) and were EUR 2.4 million (2.5). APAC accounted for 73.3% (66.4%) of the company's total net sales, EMEA for 21.7% (28.6%), and the Americas for 5.1% (5.1%).

Net sales from medical applications increased by 13.8% (-23.1%) and were EUR 21.4 (18.8) million. Net sales from security applications decreased by -24.4% (28.8%) and were EUR 15.9 (21.1) million. Net sales from industrial applications increased by 4.2% (24.8%) and were EUR 9.3 (8.9) million. Medical applications accounted for 45.9% (38.5%) of total net sales, security applications 34.1% (43.2%), and industrial applications 20.0% (18.3%).

The share of the five largest customers in Detection Technology's total net sales was 55.8% (52.1%).

NET SALES BY BUSINESS UNITS

(EUR 1,000)	4-6/2025	4-6/2024	Change, %	1-6/2025	1-6/2024	Change, %	1-12/2024
Americas	1,485	1,567	-5.2%	2,356	2,473	-4.8%	6,591
APAC	18,193	16,749	8.6%	34,162	32,388	5.5%	70,525
EMEA	4,694	7,777	-39.6%	10,103	13,937	-27.5%	30,398
TOTAL	24,372	26,093	-6.6%	46,621	48,799	-4.5%	107,514

NET SALES BY MAIN APPLICATIONS

(EUR 1,000)	4-6/2025	4-6/2024	Change, %	1-6/2025	1-6/2024	Change, %	1-12/2024
Industrial	5,565	5,340	4.2%	9,319	8,943	4.2%	19,038
Medical	10,560	9,273	13.9%	21,392	18,798	13.8%	42,190
Security	8,247	11,480	-28.2%	15,910	21,058	-24.4%	46,285
TOTAL	24,372	26,093	-6.6%	46,621	48,799	-4.5%	107,514

Operating result and profitability

Detection Technology's operating profit (EBITA) in Q2 2025 amounted to EUR 1.7 (3.3) million, or 7.0% (12.7%) of total net sales. The Q2 profitability was impacted by a decline in sales and a less favorable sales mix.

Q2 fixed costs were EUR 9.7 (9.8) million, out of which personnel expenses totaled EUR 5.9 (6.2), depreciation and goodwill amortization EUR 0.7 (0.9) and other operating expenses EUR 3.1 (2.8) million. Financial items amounted to EUR 0.6 (0.4), and income taxes were EUR -0.2 (0.4) million.

The Q2 result totaled EUR 1.0 (2.2) million. Earnings per share were EUR 0.07 (0.15). Earnings per share (diluted) were EUR 0.07 (0.15).

For H1 2025, the operating profit (EBITA) was EUR 3.1 (5.6) million, or 6.7% (11.4%) of net sales.

In H1, fixed costs were EUR 18.8 (19.0) million, out of which personnel expenses totaled EUR 11.7 (11.8) million, depreciations and goodwill amortization EUR 1.5 (1.7) million and other operating expenses EUR 5.7 (5.5) million. Financial items totaled EUR 0.8 (0.4) million, and income taxes were EUR 0.0 (0.8) million.

The result for H1 2025 was EUR 1.7 million (3.8). Earnings per share were EUR 0.11 (0.26). Earnings per share (diluted) were EUR 0.11 (0.26).

Cash flow and financing

Cash flow from operations in Q2 2025 was EUR 0.5 (3.9) million. Cash flow from operations in H1 2025 amounted to EUR 1.9 (6.8) million. The decline in cash flow in Q2 was mainly driven by lower EBITA.

Cash flow from financing activities in Q2 was EUR -7.3 (-8.7) million. Cash flow from financing activities in H1 was EUR -7.3 (-9.7) million.

A dividend of EUR 7.3 (3.4) million, resolved at the Annual General Meeting on 27 March 2025, was paid.

In Q2, the change in short-term loans was EUR 0 (-2.1) million and long-term loans EUR 0 (-3.2) million. In H1, the change in short-term loans was EUR 0 (-2.1) million and long-term loans EUR 0 (-4.2) million.

At the end of the review period, the company's net interest-bearing debt totaled EUR -19.8 (-14.7) million, and gearing was -27.2% (-19.9%).

Cash and cash equivalents amounted to EUR 20.2 (14.9) million at the end of the review period.

The company has secured its liquidity by agreeing with banks on lines of credit totaling EUR 22.9 (24.3) million at the closing rate of the review period. At the end of the review period, the unused line of credit was EUR 22.4 (24.1) million.

The company's net working capital decreased during Q2 by EUR 0.3 million and during H1 by EUR 0.7 million.

Investments

Investments in Q2 2025 totaled EUR 1.1 (0.4) million. Investments were mainly made in long-term R&D capabilities, as well as production equipment and machines. Investments in H1 2025 totaled EUR 1.5 (1.5) million.

Research and development

In Q2 2025, research and development (R&D) costs, including depreciations, totaled EUR 3.1 (3.0) million, 12.9% (11.7%) of net sales. In H1 2025, R&D expenses were EUR 5.8 (5.6) million, corresponding to 12.4% (11.4%) of net sales. All R&D costs have been recognized as expenses.

Personnel

At the end of June 2025, Detection Technology employed 494 (464) people. A total of 376 people worked in China, 102 in Finland, 10 in France, 3 in India and 3 in the U.S. Personnel expenses in Q2 2025 amounted to EUR 5.9 million (6.2). In H1 2025, personnel expenses totaled EUR 11.7 (11.8) million.

PERSONNEL BY GEOGRAPHY

	30.6.2025	30.6.2024	Change, %	31.12.2024
APAC	376	355	5.9%	378
Americas	3	4	-25.0%	4
EMEIA	115	105	9.5%	105
TOTAL	494	464	6.5%	487

Changes in the management group

As of 23 May 2025, Bree Allen stepped down from his role as President of the Americas Business Unit and as a member of Detection Technology's management group. Arve Lukander, President of the EMEIA (Europe, Middle East, India and Africa) Business Unit, has assumed responsibility for the Americas Business Unit alongside his EMEIA duties. This change does not impact the company's operating or financial reporting models.

As of 23 May 2025, the management group has comprised: Hannu Martola, President and CEO; Matti Nylander, CFO; Arve Lukander, President, EMEIA and Americas Business Units; Chen Wu, President, APAC Business Unit; Juha Talasmäki, Vice President, Business Development; Sari Holopainen, Vice President, People and Culture; Jyrki Still, CTO; and Kai Utela, Vice President, Operations.

Strategy implementation

During H1 2025, Detection Technology maintained strong momentum in strategic marketing and sales for its flat panel detector portfolio. Thanks to the development of a comprehensive portfolio and its global availability, sales of flat panel detectors for industrial applications grew by approximately 40% in January–June 2025 compared to the corresponding period in 2024. The growth was primarily fueled by heightened demand in battery and electronics inspection applications. Concurrently, the company has reinforced its positioning in the medical segment, with advancements driven by IGZO-TFT solutions.

The company launched the unique X-Panel 43108a FQI detector, which has generated strong interest. It features the largest single-glass TFT X-ray sensor on the market, with an active imaging area of 43 × 108 cm, and a frame rate more than three times higher than conventional solutions. This enables the inspection of large components in a single scan, significantly improving production efficiency and throughput times. It is well-suited for demanding industrial applications, including the automotive, aerospace, and defense industries. Sales have commenced, and first deliveries are scheduled for late 2025.

Another significant strategic launch was X-Cargo, developed for high-speed, high-energy cargo and industrial inspection. It enables scanning speeds of up to 70 km/h and supports large system configurations with a new control board capable of operating up to 80 detector modules. Its matrix structure, featuring up to eight photodiode rows, significantly enhances image quality. The modular design provides flexibility, simplifies maintenance, and supports sustainability. Investments in border security are increasing, resulting in a successful start of sales.

Furthermore, the company launched the pioneering X-Panel 2520z FOM flat panel detector for dental imaging. It is the first solution in its size category on the market based on IGZO-TFT technology, offering a wider field of view (FOV) and improved image quality.

The expansion of the company's operations in India has progressed. The production facility has been completed, and the first products have been tested, with deliveries expected to begin in H2 2025.

In addition, the company has made an investment in new technology to support long-term growth. This reflects the company's commitment to positioning itself at the forefront of innovation.

DT2030 strategy

Detection Technology's current strategic period will conclude at the end of 2025. During H1, the company initiated a strategy renewal process aimed at defining the next five-year growth phase through to 2030. The company will present the strategy details later this year.

The forthcoming strategy will build on the company's core strengths and reinforce its position as a global leader in X-ray detector solutions. Detection Technology remains committed to its core application areas—medical, security, and industrial—and aims to drive new growth through smarter, more value-added solutions to deliver exceptional usability and service experience for customers.

Sustainability

In H1 2025, Detection Technology advanced its sustainability agenda through focused initiatives. It increased the use of green energy across operations and promoted environmental awareness among employees through internal campaigns tied to global events like Earth Hour, World Water Day, International Day for Biodiversity, and World Environment Day.

The company expanded the use of its new HRIS (Human Resources Information System) to boost process efficiency, data accuracy, and employee experience. In May, it conducted the bi-annual DT Heartbeat pulse survey, with a 79% (88%) response rate and a stable average score of 3.4/4 (3.4). Collaborative improvement actions were launched and tracked via the HRIS, which also enabled enhanced reporting, analysis, and planning.

The company held an Occupational Health Laws Publicity Week and Work Safety Month in Beijing and Wuxi, China, and conducted extensive emergency drills at multiple facilities. A single minor lost-time incident was recorded, and preventive measures were reinforced.

Through its involvement in the Ahlström Collective Impact (ACI) network with UNICEF Finland, Detection Technology continued to advance children's rights and global education. The company sustained communications and engagement efforts to drive local impact in line with global goals.

Supplier sustainability remained integral to the company's sourcing practices, with key suppliers audited and assessed. The company has not received any notifications of infringements of EU or national laws or the company's Code of Conduct through its Whistleblowing channel or other reporting channels in H1 2025.

In line with its continuous improvement strategy, Detection Technology enhanced its Lean Six Sigma (LSS) capabilities. The company completed Champion-level training for managers and delivered Yellow Belt certification programs in both English and Chinese, enhancing its culture of operational efficiency and data-driven decision-making.

Detection Technology's corporate social responsibility complies with the certified ISO standards. The company acknowledges and complies with the Code of Conduct of the Responsible Business Alliance (RBA). The company has set metrics to evaluate continuous improvement across all aspects of its Code of Conduct, and the outcome is reviewed quarterly. Further details are available in the 2024 annual review.

The company's Corporate Sustainability Reporting Directive (CSRD) reporting obligation has been postponed by two years following the EU's Omnibus proposal. Detection Technology is actively monitoring further legislative developments and will resume relevant preparations once additional clarity is provided.

Shares and shareholders

The subscription period of Detection Technology's stock options 2020B1 and 2020B2 terminated on 31 May 2025, and no subscriptions were made. This was the company's final active stock option program.

Detection Technology has a rolling Performance Share Plan (PSP). This long-term incentive scheme established for the company's management and other key employees consists of separate stock awards, which the company's Board of Directors resolve each year.

On 6 February 2025, the company announced the decision by the Board of Directors to launch the PSP 2025–2027 program. The performance period of PSP 2025–2027 started in the beginning of January 2025, and it will end at the end of 2027. The potential awards under the performance share plan will be paid in H1 2028 as listed shares of Detection Technology.

The primary performance measure on the basis of which the potential share rewards under the program will be paid is the total shareholder return (absolute TSR) of Detection Technology's share. In addition, performance is evaluated with a sustainability metric, which is connected to the reduction of carbon dioxide emissions.

If all the performance targets set for the program are fully achieved, the aggregate maximum number of shares to be paid as a reward under the plan is approximately 279,600 shares (gross earnings before the applicable withholding tax). Approximately 60 people, including management group members, are eligible to participate in the program.

The performance period of the PSP 2022–2024 program started at the beginning of August 2022 and ended at the end of 2024, and no share-based payments were made under the program. The performance period of the PSP 2023–2025 program started at the beginning of January 2023 and will finish at the end of 2025. The performance period of the PSP 2024–2026 program started in the beginning of January 2024 and will finish at the end of 2026.

The average share price of Detection Technology was EUR 12.00 in Q2 and EUR 13.55 in January-June 2025. The highest share price for Q2 was EUR 15.05 and the lowest EUR 10.45. The highest price for H1 2025 was EUR 16.65 and the lowest EUR 10.45.

The closing price at the end of June was EUR 11.15, and the company had a market capitalization of approximately EUR 163 million. The number of shares traded between 2 January and 30 June was 1.13 million, which is 7.7% of the total number of shares. The number of shares outstanding in Detection Technology was 14,655,630 at the end of the review period.

The total number of shareholders at the end of the review period was 5,278. Approximately 71.4% of the shares were held by the ten largest shareholders. The nominee-registered foreign holding of shares in the company was 12.6%.

Detection Technology has one share series, and all shares bear equal voting rights. The company's shares are listed on the Nasdaq First North Growth Market Finland marketplace under the ticker symbol DETEC.

Notifications of major holdings

Detection Technology did not receive any flagging notifications in H1 2025. The obligation to notify and disclose major changes in holdings and voting rights is set out in Chapter 9 of the Finnish Securities Markets Act.

Risks and uncertainties

The company's most significant short-term direct and indirect risk factors and uncertainties are changes in geopolitics, in particular changes in the U.S. policies and tariffs, changes in the U.S.-China and the EU-China relations, global economic uncertainty, the Russian war in Ukraine and the unrest in the Middle East, along with their ramifications on the global and European security and economy, availability and prices of energy and raw materials and the consequent increase in global political uncertainty. In addition, challenges in the availability of special materials and electronic components may have an adverse impact on the company's business.

Other risks are related to business operations in developing markets, the changes in the competitive landscape, the ongoing healthcare reform in China, price competition, a significant share of net sales being generated by the five largest customers, APAC countries' large share of sales, customer liquidity, product quality, the startup of production of new products, exchange rate fluctuations, overall cost development particularly in China, the permanence and competence of personnel, recruitment of experts and organizational efficiency.

Additional risks related to the company and its business operations are described in the 2024 financial statements. Detection Technology takes continuous measures to mitigate the risks.

Business review January-September 2025

Detection Technology will publish a business review January-September 2025 on 30 October 2025.

UNAUDITED HALF-YEARLY REPORT 1.1.-30.6.2025**ACCOUNTING PRINCIPLES**

This unaudited half-yearly report for the period 1.1.-30.6.2025 has been prepared according to Finnish Accounting Standards (FAS).

CONSOLIDATED INCOME STATEMENT (FAS)

(EUR 1,000)	4-6/2025	4-6/2024	1-6/2025	1-6/2024	1-12/2024
Net sales	24,372	26,093	46,621	48,799	107,514
Other operating income	104	61	387	585	1,249
Materials and services	-13,329	-13,285	-25,625	-25,411	-56,324
Personnel expenses	-5,900	-6,151	-11,666	-11,846	-23,920
Depreciations	-442	-581	-896	-1,097	-2,065
Other operating expenses	-3,104	-2,830	-5,721	-5,460	-11,562
EBITA	1,702	3,306	3,101	5,570	14,892
Amortizations	-282	-282	-564	-564	-1,129
Financial income and expenses	-579	-402	-820	-385	-417
Profit before taxes	840	2,622	1,716	4,620	13,347
Income taxes	169	-373	-17	-758	-2,235
Minority interest	-21	-18	-36	-25	1
Profit for the reporting period	988	2,231	1,664	3,838	11,112

CONSOLIDATED BALANCE SHEET (FAS)

(EUR 1,000)	30.6.2025	30.6.2024	31.12.2024
ASSETS			
NON-CURRENT ASSETS			
Intangible assets	10,696	11,941	11,244
Tangible assets	3,891	4,465	4,427
Investments	1,870	11	11
TOTAL NON-CURRENT ASSETS	16,457	16,417	15,681
CURRENT ASSETS			
Inventories	21,931	21,978	22,793
Non-current receivables	371	320	370
Current receivables	30,695	35,275	33,067
Cash and cash equivalents	20,244	14,903	28,266
TOTAL CURRENT ASSETS	73,241	72,475	84,496
TOTAL ASSETS	89,697	88,892	100,177
EQUITY AND LIABILITIES			
EQUITY			
Share capital	80	80	80
Share premium account	5,130	5,130	5,130
Invested non-restricted equity fund	28,405	28,405	28,405
Retained earnings	37,385	36,328	37,634
Profit for the financial period	1,664	3,838	11,112
TOTAL EQUITY	72,664	73,781	82,361
Minority interest	211	215	195
LIABILITIES			
Non-current liabilities	0	0	0
Current liabilities	16,823	14,896	17,621
TOTAL LIABILITIES	16,823	14,896	17,621
TOTAL EQUITY AND LIABILITIES	89,697	88,892	100,177

CONSOLIDATED CASH FLOW STATEMENT (FAS)

(EUR 1,000)	4-6/2025	4-6/2024	1-6/2025	1-6/2024	1-12/2024
Cash flow from operations					
Operating profit	1,419	3,024	2,537	5,005	13,763
Depreciations	724	863	1,460	1,662	3,194
Other non-cash business activities	-1,503	389	-1,635	445	1,112
Change in working capital	340	875	684	1,696	4,906
Financial income and expenses	-250	-429	-227	-481	-755
Income taxes paid	-272	-811	-922	-1,500	-2,088
Cash flow from operations	458	3,911	1,897	6,827	20,133
Cash flow from investments					
Investments in intangible and tangible assets	-326	-352	-729	-1,485	-2,218
Payment for shares in subsidiaries and associated undertakings	-818	0	-818	0	0
Cash flow from investments	-1,144	-352	-1,548	-1,485	-2,218
Free cash flow	-686	3,559	350	5,342	17,915
Cash flow from financing					
Change in non-current loans	0	-3,200	0	-4,200	-4,200
Change in current loans	0	-2,089	0	-2,089	-1,765
Dividend paid	-7,328	-3,371	-7,328	-3,371	-3,371
Cash flow from financing	-7,328	-8,660	-7,328	-9,660	-9,336
Change in cash and cash equivalents					
Cash and cash equivalents at the beginning of the period	28,973	19,949	28,266	19,101	19,101
Foreign exchange rate effect	-715	54	-1,043	119	585
Cash and cash equivalents at the end of the period	20,244	14,903	20,244	14,903	28,266
Change in cash and cash equivalents	-8,014	-5,100	-6,979	-4,318	8,579
Change in working capital					
Change in current receivables	-2,662	-1,205	413	543	2,939
Change in inventories	-332	1,059	-1,001	1,707	1,598
Change in current liabilities	3,334	1,021	1,272	-555	370
Change in working capital	340	875	684	1,696	4,906

STATEMENT OF EQUITY CHANGES

(EUR 1,000)	Share capital	Share premium	Invested unrestricted equity fund	Retained earnings	Profit for the period	Total
Equity 1.1.2025	80	5,130	28,405	48,746	0	82,361
Dividend paid	0	0	0	-7,328	0	-7,328
Conversion differences	0	0	0	-4,043	0	-4,043
Adjustments to retained earnings	0	0	0	10	0	10
Profit for the period	0	0	0	0	1,664	1,664
Equity 30.6.2025	80	5,130	28,405	37,385	1,664	72,664
Equity 1.1.2024	80	5,130	28,405	39,190	0	72,805
Dividend paid	0	0	0	-3,371	0	-3,371
Conversion differences	0	0	0	509	0	509
Profit for the period	0	0	0	0	3,838	3,838
Equity 30.6.2024	80	5,130	28,405	36,328	3,838	73,781
Equity 1.1.2024	80	5,130	28,405	39,190	0	72,805
Dividend paid	0	0	0	-3,371	0	-3,371
Conversion differences	0	0	0	1,815	0	1,815
Profit for the period	0	0	0	0	11,112	11,112
Equity 31.12.2024	80	5,130	28,405	37,634	11,112	82,361

Espoo, Finland 6 August 2025

Board of Directors
Detection Technology Plc

CALCULATION OF KEY FINANCIAL RATIOS

EBITA	= Operating profit (EBIT) - Amortizations
Change in net sales, %	= (Net sales - Previous financial year's net sales) / Previous financial year's net sales x 100
EBITA, %	= EBITA / Net sales x 100
Net interest-bearing debt	= Interest-bearing liabilities - Cash and cash equivalents
Return on investment (ROI), %	= (Net result + Financial expenses + Taxes (12 months)) / (Equity + Interest-bearing liabilities (average 12 months)) x 100
Gearing, %	= (Interest-bearing liabilities - Cash and cash equivalents) / Equity x 100
Earnings per share, EUR	= Profit for the reporting period / Weighted average number of shares outstanding
Earnings per share (diluted), EUR	= Profit for the reporting period / Weighted average number of shares outstanding, diluted



www.deetee.com